Ixekizumab: Difference between revisions
From IDWiki
(Created page with "* Used for moderate to severe plaque psoriasis * IL-17 inhibitor * Risks include pneumonia and superficial fungal infections Category:Medications") |
No edit summary |
||
| Line 1: | Line 1: | ||
* Used for moderate to severe plaque psoriasis |
* Used for moderate to severe plaque psoriasis |
||
| + | * Anti-IL-17A monoclonal antibody |
||
| − | * IL-17 inhibitor |
||
| + | |||
| − | * Risks include pneumonia and superficial fungal infections |
||
| + | == Adverse Events == |
||
| + | |||
| + | * Common: [[neutropenia]], [[Hypersensitivity reaction|hypersensitivity reactions]], infections including pneumonia, injection site reactions |
||
| + | * Uncommon: superficial fungal infections, nausea, [[thrombocytopenia]], antibody development |
||
| + | * Rare: [[Crohn disease]] and [[ulcerative colitis]] (including causing exacerbations), [[oral candidiasis]], [[influenza]], [[conjunctivitis]], and [[rhinitis]] |
||
[[Category:Medications]] |
[[Category:Medications]] |
||
Latest revision as of 19:31, 12 February 2022
- Used for moderate to severe plaque psoriasis
- Anti-IL-17A monoclonal antibody
Adverse Events
- Common: neutropenia, hypersensitivity reactions, infections including pneumonia, injection site reactions
- Uncommon: superficial fungal infections, nausea, thrombocytopenia, antibody development
- Rare: Crohn disease and ulcerative colitis (including causing exacerbations), oral candidiasis, influenza, conjunctivitis, and rhinitis
